Show simple item record

dc.creatorLove, Ebony
dc.creatorGarcia, Michelle
dc.creatorLabbad, Ziad G.
dc.identifier.citationLove E, Garcia M, Labbad Z. Overview of diabetic neuropathy and review of FDA-approved oral therapies. The Foot & Ankle Online Journal [Internet]. 2020 Dec 31;13(4). Available from: doi: 10.3827/faoj.2020.1304.0002
dc.description.abstractDiabetic neuropathy is the most common complication of uncontrolled and chronic diabetes. Neuropathy is the result when the somatosensory system is compromised leaving patients with irreversible nerve damage. The continuity of this neuropathic pain may lead to disorders such as insomnia, depression, and anxiety. The cause of neuropathic pain cannot be treated, and current treatment management focuses on treating the symptoms. A review of current literature on diabetic neuropathy and of FDA approved oral therapies is performed to provide an extensive overview in order to reduce and prevent the progression of this disease. The epidemiology of diabetic neuropathy can be characterized by its prevalence and risk factors. Symmetric polyneuropathy is the most common type of diabetic neuropathy accounting for about 75% of affected patients and is divided into classes depending on the types of sensory fibers involved. Small fiber neuropathy is associated with burning, prickling pain due to non-painful stimuli or an exaggerated response to painful stimuli. Large fiber affected neuropathy involves numbness, tingling without pain, and loss of protective sensation. Besides lifestyle intervention and glucose control the first line medication for diabetic neuropathy is gabapentin, pregabalin and duloxetine. This literature review guide is dedicated to the millions suffering from diabetic neuropathy. Neuropathic pain is a chronic disorder that can impair a patient’s quality of life. The results of this literature review demonstrate a need for long-term research with advancing technologies on new medications to understand their specific effects and risks to patients.
dc.format.extent3 pages
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartThe Foot and Ankle Online Journal, Vol. 13
dc.relation.isreferencedbyInternational Foot & Ankle Foundation
dc.rightsAttribution CC BY
dc.subjectDiabetic neuropathy
dc.subjectFDA warning for gabapentinoids
dc.titleOverview of diabetic neuropathy and review of FDA-approved oral therapies
dc.type.genreJournal article
dc.description.departmentPodiatric Medicine
dc.description.departmentPodiatric Biomechanics
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.description.schoolcollegeTemple University. School of Podiatric Medicine
dc.temple.creatorLove, Ebony
dc.temple.creatorGarcia, Michelle
dc.temple.creatorLabbad, Ziad

Files in this item

LoveEtAl-JournalArticle-2020-1 ...

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY